Effects of probiotics on pentylenetetrazol-induced convulsions in mice

Sabouri, Salehe; Kangi, Sahar; Najimi, Sara; Rahimi, Hamid Reza

doi:10.1016/j.eplepsyres.2021.106723

Cited by 5 publications

(2 citation statements)

References 40 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…For instance, the supplementation of probiotics and NS (N-stearoyl-L-tyrosine) reduced population spike-long-term potentiation (PS-LTP) in kindled rats, thereby improving seizure-induced cognitive impairment (Gong et al, 2020). Other animal models have also demonstrated the potential anti-seizure effects of probiotics (Tahmasebi et al, 2020;Eor et al, 2021;Kilinc et al, 2021;Sabouri et al, 2021;Mu et al, 2022b;Wang et al, 2022;Ciltas et al, 2023).…”

Section: Fmt Probiotics and Epilepsy Treatmentmentioning

confidence: 99%

The interplay between microbiota and brain-gut axis in epilepsy treatment

Zhu,

Wang,

2024

Front. Pharmacol.

View full text Add to dashboard Cite

The brain-gut axis plays a vital role in connecting the cognitive and emotional centers of the brain with the intricate workings of the intestines. An imbalance in the microbiota-mediated brain-gut axis extends far beyond conditions like Irritable Bowel Syndrome (IBS) and obesity, playing a critical role in the development and progression of various neurological disorders, including epilepsy, depression, Alzheimer’s disease (AD), and Parkinson’s disease (PD). Epilepsy, a brain disorder characterized by unprovoked seizures, affects approximately 50 million people worldwide. Accumulating evidence suggests that rebuilding the gut microbiota through interventions such as fecal microbiota transplantation, probiotics, and ketogenic diets (KD) can benefit drug-resistant epilepsy. The disturbances in the gut microbiota could contribute to the toxic side effects of antiepileptic drugs and the development of drug resistance in epilepsy patients. These findings imply the potential impact of the gut microbiota on epilepsy and suggest that interventions targeting the microbiota, such as the KD, hold promise for managing and treating epilepsy. However, the full extent of the importance of microbiota in epilepsy treatment is not yet fully understood, and many aspects of this field remain unclear. Therefore, this article aims to provide an overview of the clinical and animal evidence supporting the regulatory role of gut microbiota in epilepsy, and of potential pathways within the brain-gut axis that may be influenced by the gut microbiota in epilepsy. Furthermore, we will discuss the recent advancements in epilepsy treatment, including the KD, fecal microbiota transplantation, and antiseizure drugs, all from the perspective of the gut microbiota.

show abstract

Section: Fmt Probiotics and Epilepsy Treatmentmentioning

confidence: 99%

The interplay between microbiota and brain-gut axis in epilepsy treatment

Zhu,

Wang,

2024

Front. Pharmacol.

View full text Add to dashboard Cite

show abstract

“…However, they enhanced the antiseizure effects of the anticonvulsant drug diazepam (DZP) and protected against the blockage of the effects of DZP by flumazenil (FLZ). The study suggested that the actions would involve GABAergic mechanisms, as DZP increases GABA actions while FLZ is a GABA A receptor antagonist [ 153 ]. Yet, generally, probiotics in preclinical studies have shown beneficial effects in countering seizures.…”

Section: Potential Dietary Treatments: Pro/prebioticsmentioning

confidence: 99%

Role of Short Chain Fatty Acids in Epilepsy and Potential Benefits of Probiotics and Prebiotics: Targeting “Health” of Epileptic Patients

et al. 2022

View full text Add to dashboard Cite

The WHO’s definition of health transcends the mere absence of disease, emphasizing physical, mental, and social well-being. As this perspective is being increasingly applied to the management of chronic diseases, research on gut microbiota (GM) is surging, with a focus on its potential for persistent and noninvasive dietary therapeutics. In patients with epilepsy (PWE), a chronic lack of seizure control along with often neglected psychiatric comorbidities greatly disrupt the quality of life. Evidence shows that GM-derived short chain fatty acids (SCFAs) may impact seizure susceptibility through modulating (1) excitatory/inhibitory neurotransmitters, (2) oxidative stress and neuroinflammation, and (3) psychosocial stress. These functions are also connected to shared pathologies of epilepsy and its two most common psychiatric consequences: depression and anxiety. As the enhancement of SCFA production is enabled through direct administration, as well as probiotics and prebiotics, related dietary treatments may exert antiseizure effects. This paper explores the potential roles of SCFAs in the context of seizure control and its mental comorbidities, while analyzing existing studies on the effects of pro/prebiotics on epilepsy. Based on currently available data, this study aims to interpret the role of SCFAs in epileptic treatment, extending beyond the absence of seizures to target the health of PWE.

show abstract